Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Health Catalyst Inc (NASDAQ: HCAT) closed at $2.72 in the last session, down -1.45% from day before closing price of $2.76. In other words, the price has decreased by -$1.45 from its previous closing price. On the day, 0.79 million shares were traded. HCAT stock price reached its highest trading level at $2.88 during the session, while it also had its lowest trading level at $2.63.
Ratios:
We take a closer look at HCAT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.86 and its Current Ratio is at 1.86. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.50.
Cantor Fitzgerald Downgraded its Overweight to Neutral on August 08, 2025, while the target price for the stock was maintained at $4.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when David Ross bought 4,793 shares for $2.90 per share.
Linda Llewellyn bought 9,762 shares of HCAT for $28,311 on Dec 01 ’25. On Dec 01 ’25, another insider, Jason Alger, who serves as the Officer of the company, bought 20,619 shares for $2.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 192388000 and an Enterprise Value of 272967008. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.61 while its Price-to-Book (P/B) ratio in mrq is 0.58. Its current Enterprise Value per Revenue stands at 0.864 whereas that against EBITDA is -16.203.
Stock Price History:
The Beta on a monthly basis for HCAT is 1.68, which has changed by -0.6654545 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $8.91, while it has fallen to a 52-week low of $2.02. The 50-Day Moving Average of the stock is -4.41%, while the 200-Day Moving Average is calculated to be -24.82%.
Shares Statistics:
According to the various share statistics, HCAT traded on average about 661.76K shares per day over the past 3-months and 884600 shares per day over the past 10 days. A total of 70.62M shares are outstanding, with a floating share count of 65.96M. Insiders hold about 6.75% of the company’s shares, while institutions hold 78.27% stake in the company. Shares short for HCAT as of 1763078400 were 6060201 with a Short Ratio of 9.16, compared to 1760486400 on 6632700. Therefore, it implies a Short% of Shares Outstanding of 6060201 and a Short% of Float of 9.7600006.
Earnings Estimates
A comprehensive evaluation of Health Catalyst Inc (HCAT) is underway, with the input of 8.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.08, with high estimates of $0.15 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.25 and $0.18 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.35, with 10.0 analysts recommending between $0.62 and $0.21.
Revenue Estimates
According to 11 analysts,. The current quarter’s revenue is expected to be $73.94M. It ranges from a high estimate of $75.04M to a low estimate of $73.5M. As of. The current estimate, Health Catalyst Inc’s year-ago sales were $79.61MFor the next quarter, 11 analysts are estimating revenue of $74.21M. There is a high estimate of $76.4M for the next quarter, whereas the lowest estimate is $71.96M.
A total of 12 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $311.49M, while the lowest revenue estimate was $309.9M, resulting in an average revenue estimate of $310.26M. In the same quarter a year ago, actual revenue was $306.58MBased on 12 analysts’ estimates, the company’s revenue will be $302.08M in the next fiscal year. The high estimate is $307.5M and the low estimate is $298.1M.
